Keywords
Half-dose priming regimen
Elderly
Acute myeloid leukemia
Submitted : 2022-04-30
Accepted : 2022-05-15
Published : 2022-05-30
Abstract
Objective: To investigate the clinical effects of combining decitabine with a half-dose priming regimen in the treatment of elderly patients with acute myeloid leukemia. Methods: This study was conducted in Shaanxi Provincial People’s Hospital from January 2019 to January 2022. Sixty patients were recruited as the research subjects. The patients received different treatments and were randomly divided into two groups, with 30 cases in each group, one of which was treated with conventional priming regimen (control group), and the other was treated with decitabine combined with a half-dose priming regimen (study group). The two groups were compared and analyzed in terms of the effectiveness of treatment. Results: The rate of symptom relief in the study group was 96.67%, which was significantly higher than that in the control group (76.67%) (p < 0.05). Before treatment, there was no significant difference in the quality-of-life scores between the two groups, with p > 0.05. The patients in the study group had significantly longer disease-free survival and overall survival than those in the control group, with p < 0.05. The effectiveness of treatment in the study group was also better. Conclusion: The use of decitabine in combination with a half-dose priming regimen for the treatment of elderly patients with acute myeloid leukemia is effective in improving patients’ quality of life, relieving symptoms, and prolonging their survival.
References
Wang HX, Bai JJ, Pei ZX, et al., 2020, Venetoclax + Hypomethylating Agents Combined with Dose-Adjusted HAG for Relapsed/Refractory Acute Myeloid Leukemia. Medicine (Baltimore), 99(47): e23265.
Wang Y, Wang X, Ren S, 2020, Clinical Efficacy of Decitabine + DAG Regimen Combined with Fostering Detoxification and Eliminating Stasis in the Treatment of Elderly Patients with Acute Myeloid Leukemia. Journal of China Medical University, 49(5): 414-418.
Jiang T, Chen H, Yang J, et al., 2020, Effectiveness of Decitabine Combined with Low-Dose HAG Regimen in the Treatment of Acute Myeloid Leukemia in the Elderly and Its Effect on Their Immune Function. Wisdom Health, 2020(14): 126-128.
Xiao W, Ou Y, 2020, Clinical Effects of Decitabine Combined with Pre-Stimulation Regimen in the Treatment of Acute Myeloid Leukemia. Journal of Clinical Rational Drug Use, 13(8): 56-58.
Han X, Cui B, Chen Y, 2020, Prognostic Evaluation of Low-Dose Decitabine Combined with Prestimulation Chemotherapy for Relapsed Refractory Elderly Acute Myeloid Leukemia. Clinical Medicine, 2020(3): 4-6.
Zhang Y, Chen P, Li WM, et al., 2021, Efficacy of Decitabine Combined with HA Regimen for the Induction Treatment of Acute Myeloid Leukemia in the Elderly. China Medical Journal, 56(1): 91-93.
Lai QY, 2020, Clinical Efficacy Analysis of Decitabine-Containing Regimen in the Treatment of Primary Acute Myeloid Leukemia, Southern Medical University.
Dong Y, Deng LJ, Zhan Z, et al., 2020, Efficacy and Safety of Decitabine Combined with Low-Dose Mitoxantrone Pre-Stimulation Regimen in the Treatment of Elderly Acute Myeloid Leukemia. Chinese Journal of Practical Internal Medicine, 40(7): 567-570.
Wang J, Lei Q, 2020, Clinical Effects of Decitabine Combined with Low-Dose HAG Regimen in the Treatment of Elderly Patients with Acute Myeloid Leukemia. Clinical Medicine Research and Practice, 5(10): 33-34.
Jia X, Chen L, Li G, et al., 2021, A Case of Relapsed Refractory Acute Myeloid Leukemia Treated with Decitabine in Combination with Venetoclax. Chinese Clinical Oncology, 48(3): 162.
Zhang Y, Wu SH, Liu J, 2020, Clinical Observation of Decitabine Combined with Half Dose CAG Regimen in the Treatment of MDS and AML. Journal of Community Medicine, 2020(22): 1532-1535.
Chen YL, Zhao WS, Guo XT, et al., 2021, Efficacy and Safety Analysis of Decitabine Combined with Prestimulation Regimen for Acute Myeloid Leukemia Failing the First Course of Standard Induction Chemotherapy. Journal of Practical Medicine, 37(14): 1800-1804.
Chen R, Zhang F, Lai GL, et al., 2020, Meta-Analysis of the Clinical Efficacy and Safety of Decitabine Combined with CAG Regimen in the Treatment of Acute Myeloid Leukemia in the Elderly. Leukemia & Lymphoma, 29(8): 488-494.
Yao X, 2021, Clinical Effectiveness of Decitabine in Combination with Prestimulation Regimen in the Treatment of Acute Myeloid Leukemia. World Compound Medicine, 7(9): 158-161.
Tian X, Xu Y, 2021, Effectiveness of Decitabine Combined with CAG Regimen in the Treatment of Acute Myeloid Leukemia at the Beginning of Old Age. Henan Medical Research, 30(1): 86-88.
Li LW, 2021, Clinical Effect Analysis of Decitabine Combined with CHG Regimen in the Treatment of High-Risk Acute Myeloid Leukemia in the Elderly. Journal of Shanxi Medicine, 50(5): 795-797.
Zhang J, 2020, Analysis of the Effect of Treating Elderly Patients with Acute Myeloid Leukemia with Low-Dose Decitabine Combined with A Modified CAG Regimen. Contemporary Medicine Series, 18(1): 99-100.
Qi HY, Wang WS, Lan JP, 2021, Clinical Efficacy of Decitabine Combined with Low-Dose IA Regimen in the Treatment of Elderly Patients with Acute Myeloid Leukemia. Zhejiang Medicine, 43(20): 2194-2197.
Li L, 2020, Effectiveness of Decitabine Combined with CAG Regimen in the Treatment of Acute Myeloid Leukemia in the Elderly. Shenzhen Journal of Integrated Chinese and Western Medicine, 30(9): 108-109.
Liu RR, Sun GZ, Peng HJ, 2020, Effectiveness and Survival Quality Analysis of Decitabine Combined with CAG in the Treatment of Elderly Acute Myeloid Leukemia (Non-APL). China Pharmaceutical Guide, 18(28): 77-78.
Qi Y, Zhao M, Xiao X, et al., 2020, Clinical Efficacy of Decitabine Combined with Reduced FLAG Regimen in the Treatment of Elderly Patients with High-Risk Acute Myeloid Leukemia. Chinese Journal of Experimental Hematology, 28(5): 1440-1444.
Zhang Y, Liu M, Zhan X, 2022, Efficacy and Safety of Decitabine Combined with Arsenic Trioxide in the Treatment of Acute Myeloid Leukemia in the Elderly. Jilin Medicine, 43(2): 1163-1166.